A shot that slashes a dangerous cholesterol
Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Surprising Findings
Lipoprotein(a) levels dropped by more than 100%—meaning they fell below baseline, effectively to near-zero.
It’s biologically unusual for a treatment to reduce a substance by over 100%, since that implies it’s not just inhibiting production but actively clearing existing particles.
Practical Takeaways
If you have high Lp(a) and heart disease, ask your doctor if you're eligible for Lp(a)-lowering trials or future approved therapies like olpasiran.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Surprising Findings
Lipoprotein(a) levels dropped by more than 100%—meaning they fell below baseline, effectively to near-zero.
It’s biologically unusual for a treatment to reduce a substance by over 100%, since that implies it’s not just inhibiting production but actively clearing existing particles.
Practical Takeaways
If you have high Lp(a) and heart disease, ask your doctor if you're eligible for Lp(a)-lowering trials or future approved therapies like olpasiran.
Publication
Journal
The New England journal of medicine
Year
2022
Authors
M. O’Donoghue, R. Rosenson, B. Gencer, J. A. López, N. Lepor, S. Baum, Elmer Stout, D. Gaudet, B. Knusel, J. Kuder, Xinhui Ran, S. Murphy, Hong Wang, You Wu, H. Kassahun, M. Sabatine
Related Content
Claims (3)
A new shot called olpasiran can slash a dangerous type of cholesterol called lipoprotein(a) by more than double its starting level in people with heart disease — meaning it doesn’t just lower it, it nearly wipes it out.
A new drug called olpasiran can dramatically lower a harmful type of cholesterol called lipoprotein(a) in people with heart disease — at the highest dose, it doesn’t just reduce it, it nearly wipes it out completely compared to a dummy pill.
For people with heart disease and high levels of a fatty protein called lipoprotein(a), a new drug called olpasiran mostly caused only mild reactions at the injection site, like redness or soreness, and was otherwise safe to use.